78782-47-5|Linogliride fumarate|(E)-N-((E)-1-methylpyrrolidin-2-ylidene)-N'-phenylmorpholine-4-carboximidamide fumarate|-范德生物科技公司

Linogliride fumarate

NMR下载 COA and HPLC MSDS下载
names：
(E)-N-((E)-1-methylpyrrolidin-2-ylidene)-N'-phenylmorpholine-4-carboximidamide fumarate
CAS号：
78782-47-5
MDL Number：
MF(分子式)： C20H26N4O5 MW(分子量)： 402.45
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Linogliride fumarate
英文别名	Linogliride fumarate; McN-3935; McN 3935; McN3935;
CAS号	78782-47-5
Inchi	InChI=1S/C16H22N4O.C4H4O4/c1-19-9-5-8-15(19)18-16(20-10-12-21-13-11-20)17-14-6-3-2-4-7-14;5-3(6)1-2-4(7)8/h2-4,6-7H,5,8-13H2,1H3;1-2H,(H,5,6)(H,7,8)/b17-16-,18-15+;2-1+
InchiKey	ZSAMTXUUUFXIII-CZKNSKRSSA-N
分子式 Formula	C20H26N4O5
分子量 Molecular Weight	402.45
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Linogliride fumarate(CAS:78782-47-5):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Linogliride fumarate is an antidiabetic agent.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Levin PA, Jovanovic L, Chalew SA, Martin L, Pitarra DK, Kim F, Kowarski AA. Linogliride fumarate, representing a new class of oral hypoglycemic agent for diabetes. Clin Pharmacol Ther. 1987 Nov;42(5):498-503. PubMed PMID: 3315390.

[2]Ronner P, Cheong E, Khalid P, Tuman RW, Matschinsky FM. Effect of linogliride on hormone release from perfused rat pancreas. Fuel dependence and desensitization by tolbutamide. Diabetes. 1991 Jul;40(7):878-84. PubMed PMID: 2060724.

[3] Ronner P, Higgins TJ, Kimmich GA. Inhibition of ATP-sensitive K+ channels in pancreatic beta-cells by nonsulfonylurea drug linogliride. Diabetes. 1991 Jul;40(7):885-92. PubMed PMID: 2060725.

[4] Salhanick AI, Leighty SJ, Amatruda JM. Postreceptor regulation of insulin action in primary cultures of rat hepatocytes by oral hypoglycemic agents: effects of linogliride and chlorpropamide. Horm Metab Res. 1989 Nov;21(11):596-601. PubMed PMID: 2687145.

[5] Wu WN, Mutter MS. Biotransformation of linogliride, a hypoglycemic agent in laboratory animals and humans. J Pharm Biomed Anal. 1995 Jun;13(7):857-67. PubMed PMID: 8562609.

6: Zawalich WS, Rasmussen G, Tuman RW, Tutwiler GF. Influence of the oral hypoglycemic agent linogliride (McN-3935) on insulin secretion from isolated rat islets of Langerhans. Endocrinology. 1987 Mar;120(3):880-5. PubMed PMID: 3542516.7: Woodfork KA, Wonderlin WF, Peterson VA, Strobl JS. Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture. J Cell Physiol. 1995 Feb;162(2):163-71. PubMed PMID: 7822427.8: Ng KT, Holland ML, Plutte JA. Determination of linogliride in biological fluids by high-performance liquid chromatography. J Chromatogr. 1984 Nov 28;311(2):418-23. PubMed PMID: 6520190.9: Klimatcheva E, Wonderlin WF. An ATP-sensitive K(+) current that regulates progression through early G1 phase of the cell cycle in MCF-7 human breast cancer cells. J Membr Biol. 1999 Sep 1;171(1):35-46. PubMed PMID: 10485992.10: Chrzanowski FA, Ahmad K. The preparation and evaluation of salt forms of linogliride with reduced solubilities as candidates for extended release. Drug Dev Ind Pharm. 2017 Mar;43(3):421-431. doi: 10.1080/03639045.2016.1257019. Epub 2016 Nov 21. PubMed PMID: 27808569.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开